MP14-08 A MULTICENTER ASSESSMENT OF SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC) WHO RECEIVED IMMUNE CHECKPOINT INHIBITOR THERAPY (ICI) WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN)

Evan Gross,Mingjia Li,Ming Yin,Delaney Orcutt,Duncan Hussey,Elliot Trott,Joel Kramer,Kaylee Oliva,John C. Gore,George R. Schade,Daniel W. Lin,Scott S. Tykodi,Evan T. Hall,John F. Thompson,Anish B. Parikh,Yuanquan Yang,Katharine A. Collier,Abdul Miah,Sherry Mori-Vogt,Megan Hinkley,Amir Mortazavi,Paul Monk,Edmund Folefac,Steven K. Clinton,Sarah P. Psutka

MP14-08 A MULTICENTER ASSESSMENT OF SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC) WHO RECEIVED IMMUNE CHECKPOINT INHIBITOR THERAPY (ICI) WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN)

2021

INTRODUCTION AND OBJECTIVE:The role of CN in the treatment of mRCC has been questioned with the recent approval of novel systemic therapy (ST) agents and the results of the CARMENA trial. Our objec...

Keywords:

Renal cell carcinoma
Oncology
Internal medicine
in patient
cytoreductive nephrectomy
Systemic therapy
Medicine
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations